Drug intelligence / Profile preview

KINE-201A

Development stage: Preclinical
Lead developer: Kine Sciences
Modality: Peptides

Overview

KINE-201A is a peptide-based therapeutic candidate currently in preclinical development by Kine Science for the treatment of atopic dermatitis. It is designed to modulate T-helper 2 (Th2) cells, which are central to the allergic and inflammatory immune responses that drive the pathogenesis of atopic dermatitis. By targeting the Th2 pathway, KINE-201A aims to suppress the overproduction of pro-inflammatory cytokines and restore immune homeostasis in the skin. The drug is part of a broader platform of peptide modulators developed by Kine Science to address various allergic and inflammatory conditions.

Beyond the preview

Go deeper on KINE-201A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KINE-201A.

Explore the full profile